期刊文献+

National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China 被引量:5

National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China
原文传递
导出
摘要 Background Long-term use of antiplatelet agents, statins, beta-blockers and angiotensin-converting enzyme inhibitors are proven therapies for secondary prevention in acute coronary syndrome. However, little is known of physicians' opinion about their use in China. Methods In 2010, standard questionnaires were posted to chief cardiologists in 1397 geographically diverse and representative sample of tertiary and secondary hospitals in China, collecting information about their opinions on the recommended treatments for acute coronary syndrome. Results A total of 1009 (72%) cardiologists responded with a valid questionnaire. Of them, 77% reported routine use of all the four main secondary preventive treatments, with little difference between secondary and tertiary hospitals (75% vs. 79%, P=0.16). Of the cardiologists reporting routine or selective use of aspirin, beta-blockers, statins and angiotensin-converting enzyme inhibitors, 94%, 85%, 73% and 86% would recommend indefinite use respectively. For all the 4 treatments combined, only 63.5% reported indefinite use at the same time, with no significant difference between secondary and tertiary hospitals (62% vs. 65%, P=0.17), nor between hospitals with or without fast track for primary percutaneous coronary intervention (66% vs. 61%, P=0.50). Conclusions Although Chinese cardiologists seem we treatments for acute coronary syndrome, there is still gap in use of these treatments. informed about the value of main secondary preventive their understanding of the need for combined and prolonged Background Long-term use of antiplatelet agents, statins, beta-blockers and angiotensin-converting enzyme inhibitors are proven therapies for secondary prevention in acute coronary syndrome. However, little is known of physicians' opinion about their use in China. Methods In 2010, standard questionnaires were posted to chief cardiologists in 1397 geographically diverse and representative sample of tertiary and secondary hospitals in China, collecting information about their opinions on the recommended treatments for acute coronary syndrome. Results A total of 1009 (72%) cardiologists responded with a valid questionnaire. Of them, 77% reported routine use of all the four main secondary preventive treatments, with little difference between secondary and tertiary hospitals (75% vs. 79%, P=0.16). Of the cardiologists reporting routine or selective use of aspirin, beta-blockers, statins and angiotensin-converting enzyme inhibitors, 94%, 85%, 73% and 86% would recommend indefinite use respectively. For all the 4 treatments combined, only 63.5% reported indefinite use at the same time, with no significant difference between secondary and tertiary hospitals (62% vs. 65%, P=0.17), nor between hospitals with or without fast track for primary percutaneous coronary intervention (66% vs. 61%, P=0.50). Conclusions Although Chinese cardiologists seem we treatments for acute coronary syndrome, there is still gap in use of these treatments. informed about the value of main secondary preventive their understanding of the need for combined and prolonged
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第18期3451-3455,共5页 中华医学杂志(英文版)
关键词 coronary heart disease acute coronary syndrome secondaryprevention coronary heart disease acute coronary syndrome secondaryprevention
  • 相关文献

参考文献2

二级参考文献40

  • 1谭慧琼,朱俊,梁岩,章晏,刘力生,代表OASIS登记试验中国地区协作组.非ST段抬高的急性冠状动脉综合征二年随访[J].中华医学杂志,2005,85(3):184-188. 被引量:12
  • 2SONG Xian-tao CHEN Yun-dai PAN Wei-qi LU Shu-zheng.Gender based differences in patients with acute coronary syndrome:findings from Chinese Registry of Acute Coronary Events (CRACE)[J].Chinese Medical Journal,2007(12):1063-1067. 被引量:9
  • 3World Health Organization. The global burden of disease: 2004 update. 2004. (Accseesd September 2011 at http://www, who.Int/healthinfo/global burden_disease/2004_report_update/en/index, html).
  • 4Hu SS, Kong LZ. Report on cardiovascular diseases in China (2007). Beijing, National Center for Cardiovascular Diseases, Encyclopedia of China Publishing House, 2008.
  • 5Center for of Health. survey in Science& Health Statistics and Information, China Ministry An analysis report of national health services 2003. Beijing, Chinese Academy of Medical Peking Union Medical College Pres, 2004.
  • 6Chinese Medical Association Ischemic Stroke Guidelines Working Group. Guidelines for secondary prevention of ischaemic stroke and transient ischaemic attack. Chin J Neuro[ (Chin) 2010; 43: 154-160.
  • 7Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials ofstatins. I ,~neet v. hh~. "~6~,. 1 "~67- J "~TR.
  • 8Joint Committee for Developing Chinese Prevention and Treatment of Dyslipidemia in guidelines on prevention and treatment of adults. Chin J Cardiol (Chin) 2007: 35:390-4 Guidelines on Adults. Chinese dyslipidemia in 19.
  • 9Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130-2139.
  • 10Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397-401.

共引文献9

同被引文献31

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部